Re: INDICES> Celecoxib

[Joel Lexchin <joel.lexchin@utoronto.ca>]

Celecoxib/Celebrex is not superior to other NSAIDs in terms of its actions.
It is being marketed as being safer, i.e., fewer gastrointestinal problems.
So far though this increased safety has not been directly demonstrated.
The company has used surrogate markers rather than direct clinical data.
Patients treated with Celecoxib have fewer endoscopically proven GI ulcers
than those treated with other NSAIDs but whether this means fewer
significant GI bleeds is as yet unknown. What is known is that Celecoxib is
much more expensive than older NSAIDs.

Joel Lexchin

Joel Lexchin MD
121 Walmer Rd.
Toronto, Ontario
CANADA M5R 2X8
Phone:  (416)-964-7186
Fax:  (416)-923-9515
e mail:  joel.lexchin@utoronto.ca



--
Send mail for the `INDICES' conference to `indices@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-indices@usa.healthnet.org'.